Syndax’s Revuforj Q4 Revenue Jumps 38% to $44.2M, 1,050 Patients Treated
Revuforj generated $124.8 million in net revenue in its first full year with Q4 net sales of $44.2 million, up 38%, and prescriptions rising 35% quarter-over-quarter. New patient starts climbed 20% to 1,050 total treated, reaching ~50% penetration in KMT2A AML, while NPM1 expansion triples addressable patients to 6,500.
1. Commercial Performance Soars
Revuforj achieved net revenues of $44.2 million in the fourth quarter, a 38% increase from Q3, contributing to $124.8 million in net revenue for 2025. Total prescriptions rose approximately 35% quarter-over-quarter, reflecting strong uptake across both academic and community oncology settings.
2. Patient Uptake and KMT2A Penetration
New patient starts increased about 20% in Q4, bringing the cumulative commercial patient count to roughly 1,050 since launch. With most patients in the KMT2A-rearranged AML segment, Syndax estimates it has captured nearly 50% of the incident KMT2A population in this first year.
3. NPM1 Label Expansion Triples Market
The expanded FDA label for NPM1-mutated AML, approved in October, triples the annual addressable Revuforj population to about 6,500 patients. Formularies now cover 97% of lives, and early indicators show NPM1 cases rising to 30% of new starts in Q4, with potential for a 50/50 split against KMT2A.